(R,S)-Ivosidenib ((R,S)-AG-120) is the racemic form of an inhibitor targeting the mutant isocitrate dehydrogenase 1 (IDH1) enzyme. It is structurally related to Ivosidenib, which is investigated in research for treating cancers associated with IDH1 mutations, particularly acute myeloid leukemia (AML). The compound works by inhibiting the mutated IDH1 enzyme, thereby reducing the production of the oncometabolite 2-hydroxyglutarate (2-HG). This action helps to restore normal cellular differentiation and may promote cancer cell death. It is commonly used in laboratory and preclinical studies to explore IDH1-related pathways and develop targeted therapies, including potential combinations with other agents. Ongoing research also examines its application in other IDH1-mutated cancers.